129 related articles for article (PubMed ID: 34966148)
1. Lower Incidence of HIV-1 Blips Observed During Integrase Inhibitor-Based Combination Antiretroviral Therapy.
Dijkstra S; Hofstra LM; Mudrikova T; Wensing AMJ; Oomen PGA; Hoepelman AIM; van Welzen BJ
J Acquir Immune Defic Syndr; 2022 Apr; 89(5):575-582. PubMed ID: 34966148
[TBL] [Abstract][Full Text] [Related]
2. Integrated analysis of viral blips, residual viremia, and associated factors in people with HIV: Results from a retrospective cohort study.
Oomen PGA; Dijkstra S; Hofstra LM; Nijhuis MM; Verbon A; Mudrikova T; Wensing AMJ; Hoepelman AIM; Van Welzen BJ
J Med Virol; 2023 Oct; 95(10):e29178. PubMed ID: 37861450
[TBL] [Abstract][Full Text] [Related]
3. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG
Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110
[TBL] [Abstract][Full Text] [Related]
4. Incidence of low-level viremia and its impact on virologic failure among people living with HIV who started an integrase strand transfer inhibitors: a longitudinal cohort study.
Lao X; Zhang H; Deng M; Li Q; Xiao Q; He L; Ma L; Song A; Liang X; Yu F; Zhao H; Zhang F
BMC Infect Dis; 2024 Jan; 24(1):8. PubMed ID: 38166689
[TBL] [Abstract][Full Text] [Related]
5. Virologic Failure Following Low-level Viremia and Viral Blips During Antiretroviral Therapy: Results From a European Multicenter Cohort.
Elvstam O; Malmborn K; Elén S; Marrone G; García F; Zazzi M; Sönnerborg A; Böhm M; Seguin-Devaux C; Björkman P
Clin Infect Dis; 2023 Jan; 76(1):25-31. PubMed ID: 36100984
[TBL] [Abstract][Full Text] [Related]
6. Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort.
Álvarez H; Rava M; Martínez C; Portilla J; Peraire J; Rivero A; Cervero M; Mariño A; Poveda E; Llibre JM;
HIV Med; 2022 Sep; 23(8):825-836. PubMed ID: 35234328
[TBL] [Abstract][Full Text] [Related]
7. Plasma Human Immunodeficiency Virus 1 RNA and CD4+ T-Cell Counts Are Determinants of Virological Nonsuppression Outcomes With Initial Integrase Inhibitor-Based Regimens: A Prospective RESPOND Cohort Study.
Álvarez H; Mocroft A; Ryom L; Neesgaard B; Edwards S; Svedhem V; Günthard HF; Zangerle R; Smith C; Castagna A; d'Arminio Monforte A; Wit F; Stecher M; Lehman C; Mussini C; Fontas E; González E; Wasmuth JC; Sönnerborg A; De Wit S; Chkhartishvili N; Stephan C; Petoumenos K; Jaschinski N; Vannappagari V; Gallant J; Young L; Volny Anne A; Greenberg L; Martín-Iguacel R; Poveda E; Llibre JM;
Clin Infect Dis; 2023 Aug; 77(4):593-605. PubMed ID: 37052343
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of antiretroviral drug classes for the treatment of HIV infection in patients with high viral loads: a multicentre retrospective cohort study.
Adams JL; Murray M; Patel N; Sawkin MT; Boardman RC; Pham C; Kaur H; Patel D; Yager JL; Pontiggia L; Baxter J
HIV Med; 2021 Jan; 22(1):28-36. PubMed ID: 32964664
[TBL] [Abstract][Full Text] [Related]
9. Treatment success of rescue regimens after dual therapy failure in people living with HIV in a real-life setting.
Clemente T; Galli L; Poli A; Papaioannu Borjesson R; Bresciani L; Muccini C; Canetti D; Candela C; Bossolasco S; Hasson H; Castagna A; Spagnuolo V
Int J Antimicrob Agents; 2023 Aug; 62(2):106897. PubMed ID: 37343809
[TBL] [Abstract][Full Text] [Related]
10. Residual viremia is preceding viral blips and persistent low-level viremia in treated HIV-1 patients.
Hofstra LM; Mudrikova T; Stam AJ; Otto S; Tesselaar K; Nijhuis M; Wensing AM
PLoS One; 2014; 9(10):e110749. PubMed ID: 25354368
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitor-based regimen.
Martinez V; Marcelin AG; Morini JP; Deleuze J; Krivine A; Gorin I; Yerly S; Perrin L; Peytavin G; Calvez V; Dupin N
AIDS; 2005 Jul; 19(10):1065-9. PubMed ID: 15958838
[TBL] [Abstract][Full Text] [Related]
12. Viral blips were infrequent in treatment-naive adults treated with rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF through 96 weeks.
Porter DP; Kulkarni R; Garner W; Miller MD; White KL
Antivir Ther; 2017; 22(6):495-502. PubMed ID: 28091393
[TBL] [Abstract][Full Text] [Related]
13. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
[TBL] [Abstract][Full Text] [Related]
14. Persistent Low-level Viremia While on Antiretroviral Therapy Is an Independent Risk Factor for Virologic Failure.
Joya C; Won SH; Schofield C; Lalani T; Maves RC; Kronmann K; Deiss R; Okulicz J; Agan BK; Ganesan A
Clin Infect Dis; 2019 Nov; 69(12):2145-2152. PubMed ID: 30785191
[TBL] [Abstract][Full Text] [Related]
15. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.
Nettles RE; Kieffer TL; Kwon P; Monie D; Han Y; Parsons T; Cofrancesco J; Gallant JE; Quinn TC; Jackson B; Flexner C; Carson K; Ray S; Persaud D; Siliciano RF
JAMA; 2005 Feb; 293(7):817-29. PubMed ID: 15713771
[TBL] [Abstract][Full Text] [Related]
16. Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen.
Varriano B; Sandler I; Loutfy M; Steinberg S; Smith G; Kovacs C; Brunetta J; Fletcher D; Knox D; Merkley B; Chang B; Tilley D; Acsai M; Crouzat F
Int J STD AIDS; 2019 Jun; 30(7):680-688. PubMed ID: 31042101
[TBL] [Abstract][Full Text] [Related]
17. Investigating rates and predictors of viral blips, low-level viraemia and virological failure in the Australian HIV observational database.
Han WM; Broom J; Bopage R; Templeton DJ; Edmiston N; Petoumenos K;
Trop Med Int Health; 2024 Jan; 29(1):42-56. PubMed ID: 38009461
[TBL] [Abstract][Full Text] [Related]
18. Virological outcome and management of persistent low-level viraemia in HIV-1-infected patients: 11 years of the Swiss HIV Cohort Study.
Boillat-Blanco N; Darling KE; Schoni-Affolter F; Vuichard D; Rougemont M; Fulchini R; Bernasconi E; Aouri M; Clerc O; Furrer H; Günthard HF; Cavassini M;
Antivir Ther; 2015; 20(2):165-75. PubMed ID: 24964403
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of integrase strand transfer inhibitors among treatment-experienced patients in a clinical setting.
Davy-Mendez T; Napravnik S; Zakharova O; Wohl DA; Farel CE; Eron JJ
AIDS; 2019 Jun; 33(7):1187-1195. PubMed ID: 30870198
[TBL] [Abstract][Full Text] [Related]
20. Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium.
Neesgaard B; Mocroft A; Zangerle R; Wit F; Lampe F; Günthard HF; Necsoi C; Law M; Mussini C; Castagna A; Monforte AD; Pradier C; Chkhartisvilli N; Reyes-Uruena J; Vehreschild JJ; Wasmuth JC; Sönnerborg A; Stephan C; Greenberg L; Llibre JM; Volny-Anne A; Peters L; Pelchen-Matthews A; Vannappagari V; Gallant J; Rieger A; Youle M; Braun D; De Wit S; Petoumenos K; Borghi V; Spagnuolo V; Tsertsvadze T; Lundgren J; Ryom L;
PLoS One; 2020; 15(12):e0243625. PubMed ID: 33382756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
